A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM)
Latest Information Update: 26 May 2023
At a glance
- Drugs Dimethyl fumarate (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms ESTEEM
- Sponsors Biogen
- 23 May 2023 Status changed from active, no longer recruiting to completed.
- 27 Apr 2023 Updated results (n=5251, As of April 2021) assessing the long-term safety and effectiveness of delayed-release dimethyl fumarate in patients with relapsing forms of multiple sclerosis in clinical practice, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
- 23 Jun 2022 Planned End Date changed from 28 Feb 2024 to 31 Oct 2022.